Mesenbio focuses on leveraging extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) to address the root causes of rheumatoid arthritis, rather than merely managing symptoms. Their innovative approach aims to repair damaged tissues and restore normal joint function, potentially reversing the disease's impact. The company has developed a proprietary platform, FT-01, which produces EVs that retain the therapeutic properties of the MSCs from which they are derived. This platform, along with FT-02 and FT-03, utilizes unique clonal cell lines to ensure consistent and pure cell populations, enabling the production of EVs with tailored therapeutic potentials for various applications in regenerative medicine.

Mesenbio's lead therapeutic asset, MEV-N01, is designed to target the underlying causes of rheumatoid arthritis by modulating the immune response and stimulating tissue regeneration. This dual-action approach allows for minimally invasive administration directly into the affected joints, aiming to delay the need for surgical interventions. The company’s extensive research over the past two decades has established the efficacy of their MSC-derived EVs, demonstrating significant improvements in joint inflammation and tissue repair in preclinical trials. By providing a scalable and consistent supply of EVs, Mesenbio is positioned to reshape the future of rheumatoid arthritis treatment through advanced regenerative therapies.

United Kingdom

Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle therapeutic is aimed at delivering next-generation medicine to patients.

Mesenbio

Company Details